Notes

Slide Show

Outline

1	"YOUNGEVITY SlenderFX™" YOUNGEVITY SlenderFX™ The New Paradigm in Weight Management
2	Metabolic Syndrome Abdominal obesity Hyperinsulinemia High fasting plasma glucose Impaired glucose tolerance Hypertriglyceridemia Low HDL-cholesterol Hypertension
3	Metabolic Syndrome Increases Risk for CHD and Type 2 Diabetes
4	Direct Cost * of Chronic Diseases in the United States
5	Global Healthcare Costs Attributed to Obesity Obesity accounts for 4% of healthcare costs in the Netherlands 3% of healthcare costs in Japan and Portugal 2% of healthcare costs in France and Australia In 2000, $117 billion of all US healthcare-related costs were from obesity or obesity-related complications
6	Increase in Healthcare Costs Among Obese Compared with Lean (BMI <25 kg/m2) Patients*
7	Relationship Between BMI and Risk of Type 2 Diabetes
8	Relationship Between BMI and Cardiovascular Disease Mortality
9	Relationship Between BMI and Percent Body Fat in Men and Women
10	Obesity Therapy
11	Trends in Weight Loss – Drug Class Intestinal lipase inhibitors Reduces fat absorption Centrally acting mixed NE/Serotonin reuptake blockers (sibutramine) Suppresses the appetite, not a thermogenic
12	Trends in Weight Loss – Non-Drug Ephedra Ephedra-free products Cortisol Glycemic index Low-carb diet
13	Regulation of Food Intake
14	YOUNGEVITY SlenderFX™ – The New Trend SlenderFX™ regulates leptin, one of the key adipocytokines produced in adipose tissue Leptin is a regulator of body fat storage as controlled through the central nervous system Leptin is instrumental in satiation, fullness, glycemic control and metabolism
15	Mechanism of Action
16
17	How Does SlenderFX™ Work? SlenderFX™ is based on a US patent The patent is based on data collected at the University of Minnesota SlenderFX™ is a blend of viscous, polysaccharides shown to reduce plasma leptin and body fat in rats
18
19	Relevant Studies Wolfe et al (Clinical Endocrinology (2004) 61, 332–338) - 4 weeks, hypocaloric diet; 15 normal-weight women; lost 3.4 kg body fat and decreased plasma leptin by ≈60% Kraemer et al (Eur J Clin Nutr (2002) 56, 585-592) – 8 weeks; dietary and exercise intervention plus supplement; 12 obese women; lost 2.5 kg body fat and decreased plasma leptin by ≈35%
20
21
22	A Successful Behavioral Approach Diet, Exercise, and SlenderFX™
23	Additive Effects of Behavior and Diet Therapy with Pharmacotherapy for Obesity
24	Physical Activity Helps Preserve Fat-Free Mass During Weight Loss
25	Insulin Sensitivity Improves with Weight Loss in Patients with Type 2 Diabetes
26	Conclusion